1. Home
  2. FLNG vs SNDX Comparison

FLNG vs SNDX Comparison

Compare FLNG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FLEX LNG Ltd.

FLNG

FLEX LNG Ltd.

N/A

Current Price

$32.72

Market Cap

1.7B

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$17.80

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLNG
SNDX
Founded
2006
2005
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
FLNG
SNDX
Price
$32.72
$17.80
Analyst Decision
Hold
Strong Buy
Analyst Count
1
13
Target Price
$23.00
$38.69
AVG Volume (30 Days)
434.5K
1.2M
Earning Date
05-13-2026
04-30-2026
Dividend Yield
9.40%
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
N/A
$107.19
Revenue Next Year
$2.14
$41.88
P/E Ratio
$19.72
N/A
Revenue Growth
N/A
627.84
52 Week Low
$24.00
$13.00
52 Week High
$33.40
$25.59

Technical Indicators

Market Signals
Indicator
FLNG
SNDX
Relative Strength Index (RSI) 59.77 35.43
Support Level $28.72 $16.93
Resistance Level $33.22 $22.40
Average True Range (ATR) 0.74 0.68
MACD 0.05 -0.19
Stochastic Oscillator 98.10 11.55

Price Performance

Historical Comparison
FLNG
SNDX

About FLNG FLEX LNG Ltd.

Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: